Cargando…

A polyamine-centric, blood-based metabolite panel predictive of poor response to CAR-T cell therapy in large B cell lymphoma

Anti-CD19 chimeric antigen receptor (CAR) T cell therapy for relapsed or refractory (r/r) large B cell lymphoma (LBCL) results in durable response in only a subset of patients. MYC overexpression in LBCL tumors is associated with poor response to treatment. We tested whether an MYC-driven polyamine...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fahrmann, Johannes F., Saini, Neeraj Y., Chia-Chi, Chang, Irajizad, Ehsan, Strati, Paolo, Nair, Ranjit, Fayad, Luis E., Ahmed, Sairah, Lee, Hun Ju, Iyer, Swaminathan, Steiner, Raphael, Vykoukal, Jody, Wu, Ranran, Dennison, Jennifer B., Nastoupil, Loretta, Jain, Preetesh, Wang, Michael, Green, Michael, Westin, Jason, Blumenberg, Viktoria, Davila, Marco, Champlin, Richard, Shpall, Elizabeth J., Kebriaei, Partow, Flowers, Christopher R., Jain, Michael, Jenq, Robert, Stein-Thoeringer, Christoph K., Subklewe, Marion, Neelapu, Sattva S., Hanash, Sam
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9729795/ https://www.ncbi.nlm.nih.gov/pubmed/36384092 http://dx.doi.org/10.1016/j.xcrm.2022.100720

Ejemplares similares

Day 30 SUV(max) predicts progression in patients with lymphoma achieving PR/SD after CAR T-cell therapy
por: Al Zaki, Ajlan, et al.
Publicado: (2022)

Axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma patients in complete metabolic response
por: Jallouk, Andrew P., et al.
Publicado: (2022)

ASCT vs CART for patients with relapsed LBCL in PR: role of TMTV
por: Strati, Paolo, et al.
Publicado: (2023)

Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma
por: Strati, Paolo, et al.
Publicado: (2020)

A MYC-Driven Plasma Polyamine Signature for Early Detection of Ovarian Cancer
por: Fahrmann, Johannes F., et al.
Publicado: (2021)

A phase 1 study of prophylactic anakinra to mitigate ICANS in patients with large B-cell lymphoma
por: Strati, Paolo, et al.
Publicado: (2023)

P1092: A PHASE II INVESTIGATOR INITIATED STUDY OF ACALABRUTINIB, LENALIDOMIDE AND RITUXIMAB (AR2) IN PATIENTS WITH PREVIOUSLY UNTREATED HIGH TUMOR BURDEN FOLLICULAR LYMPHOMA
por: Strati, Paolo, et al.
Publicado: (2023)

Cardiovascular events in patients treated with chimeric antigen receptor T-cell therapy for aggressive B-cell lymphoma
por: Steiner, Raphael E., et al.
Publicado: (2021)

15. Evaluation of Retained Immunity for Tetanus-Diphtheria and Pneumococcal Vaccines in Recipients of Cellular Therapies
por: Angelidakis, Georgios, et al.
Publicado: (2021)

Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma
por: Strati, Paolo, et al.
Publicado: (2021)

Kynureninase Upregulation Is a Prominent Feature of NFR2-Activated Cancers and Is Associated with Tumor Immunosuppression and Poor Prognosis
por: León-Letelier, Ricardo A., et al.
Publicado: (2023)

c-MYC-Driven Polyamine Metabolism in Ovarian Cancer: From Pathogenesis to Early Detection and Therapy
por: Chen, Yihui, et al.
Publicado: (2023)

Impact of histologic subtypes and treatment modality among patients with primary central nervous system lymphoma: a SEER database analysis
por: Chihara, Dai, et al.
Publicado: (2018)

Extracellular Vesicles Mediate B Cell Immune Response and Are a Potential Target for Cancer Therapy
por: Kato, Taketo, et al.
Publicado: (2020)

Extracellular Vesicles in Lung Cancer: Prospects for Diagnostic and Therapeutic Applications
por: Kato, Taketo, et al.
Publicado: (2021)

Therapy of newly diagnosed follicular lymphoma
por: Westin, Jason R., et al.
Publicado: (2012)

Pre-treatment maximum standardized uptake value predicts outcome after frontline therapy in patients with advanced stage follicular lymphoma
por: Strati, Paolo, et al.
Publicado: (2020)

Novel UHRF1-MYC Axis in Acute Lymphoblastic Leukemia
por: Park, Soyoung, et al.
Publicado: (2022)

Radiation and CAR T-cell Therapy in Lymphoma: Future Frontiers and Potential Opportunities for Synergy
por: Fang, Penny Q., et al.
Publicado: (2021)

Chimeric Antigen Receptor T-Cells in B-Acute Lymphoblastic Leukemia: State of the Art and Future Directions
por: Greenbaum, Uri, et al.
Publicado: (2020)

P1222: PACIFIC: BRENTUXIMAB VEDOTIN AND NIVOLUMAB ALONE AND THEN COMBINED WITH RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN AND PREDNISONE FOR UNTREATED PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA PATIENTS
por: Steiner, R., et al.
Publicado: (2022)

Partial omission of bleomycin for early‐stage Hodgkin lymphoma patients treated with combined modality therapy: Does incomplete ABVD lead to inferior outcomes?
por: Gunther, Jillian R., et al.
Publicado: (2020)

Plasma-Derived Extracellular Vesicles Convey Protein Signatures That Reflect Pathophysiology in Lung and Pancreatic Adenocarcinomas
por: Fahrmann, Johannes F., et al.
Publicado: (2020)

Risk assessment with low-pass whole-genome sequencing of cell-free DNA before CD19 CAR T-cell therapy for large B-cell lymphoma
por: Cherng, Hua-Jay J., et al.
Publicado: (2022)

Assessment of Radiation Doses Delivered to Organs at Risk Among Patients With Early-Stage Favorable Hodgkin Lymphoma Treated With Contemporary Radiation Therapy
por: Pinnix, Chelsea C., et al.
Publicado: (2020)

Diffuse large B-cell lymphoma in very elderly patients over 80 years old: Incorporating consolidative radiation therapy into management decisions
por: Pinnix, Chelsea C., et al.
Publicado: (2017)

Clinical Application of Sleeping Beauty and Artificial Antigen Presenting Cells to Genetically Modify T Cells from Peripheral and Umbilical Cord Blood
por: Huls, M. Helen, et al.
Publicado: (2013)

Hodgkin Lymphoma Untreated for Six Years Presenting with Tracheoesophageal Fistula
por: Westin, Jason R., et al.
Publicado: (2012)

Haploidentical vs matched unrelated donors for patients with ALL: donor age matters more than donor type
por: Mehta, Rohtesh S., et al.
Publicado: (2023)

Protein citrullination as a source of cancer neoantigens
por: Katayama, Hiroyuki, et al.
Publicado: (2021)

Application of Artificial Intelligence to Plasma Metabolomics Profiles to Predict Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
por: Irajizad, Ehsan, et al.
Publicado: (2022)

Lenalidomide plus rituximab (R(2)) in previously untreated marginal zone lymphoma: subgroup analysis and long‐term follow‐up of an open‐label phase 2 trial
por: Becnel, Melody R., et al.
Publicado: (2019)

Plasma Based Protein Signatures Associated with Small Cell Lung Cancer
por: Fahrmann, Johannes F., et al.
Publicado: (2021)

PD-L1(+) macrophages are associated with favorable features in primary mediastinal (thymic) large B-cell lymphoma
por: Steiner, Raphael E., et al.
Publicado: (2023)

Prolonged cytopenia following CD19 CAR T cell therapy is linked with bone marrow infiltration of clonally expanded IFNγ-expressing CD8 T cells
por: Strati, Paolo, et al.
Publicado: (2023)

Chimeric antigen receptor T-cell therapy for adult B-cell acute lymphoblastic leukemia: state-of-the-(C)ART and the road ahead
por: Pasvolsky, Oren, et al.
Publicado: (2023)

Caveolin-1-mediated sphingolipid oncometabolism underlies a metabolic vulnerability of prostate cancer
por: Vykoukal, Jody, et al.
Publicado: (2020)

The kynurenine pathway presents multi-faceted metabolic vulnerabilities in cancer
por: León-Letelier, Ricardo A., et al.
Publicado: (2023)

A blood-based metabolomic signature predictive of risk for pancreatic cancer
por: Irajizad, Ehsan, et al.
Publicado: (2023)

Umbilical Cord Blood Transplantation: Connecting Its Origin to Its Future
por: Sanchez-Petitto, Gabriela, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_eaq0t6id3thsr2f89likiabgc6